NCT07387666RecruitingEarly phase 1
Imaging Acetadote Metabolism in Glioblastoma
A Prospective, Open-label Phase 0 Single-center Study to Assess the Effect of Acetadote on Metabolism in Newly Diagnosed Glioblastoma
Source: ClinicalTrials.gov · Last updated 23 Jun 2026
Brief summary (registry, in English)
This goal of this clinical trial is to evaluate how Acetadote affects metabolism in patients with glioblastoma. Drugs like Acetadote, which affect the level of damage in a cell (oxidative stress), may impact brain tumor metabolism and slow the growth of brain tumors. The investigators are evaluating how Acetadote affects glioblastoma metabolism by using MRI-based methods and by determining the changes in metabolism in brain tumor tissue resected from patients with a new diagnosis of glioblastoma.
- Status (registry)
- Recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- First submitted
- 27 Jan 2026
- Start date
- 18 Jun 2026
- Primary completion date
- 1 Jul 2027
- Lead sponsor
- University of Texas Southwestern Medical Center
- Diseases
- Glioblastoma
- NCT number
- NCT07387666
What you commit to
- Study type: Interventional · Early phase 1
- Planned participants: 10
- From 18 Jun 2026 to the primary completion date, 1 Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- 1.Chemotherapy, radiotherapy, or other cancer therapy within 4 weeks prior to starting study treatment.
- 2\. Subjects must have recovered from prior treatment-related toxicities to grade 2 or baseline (excluding alopecia and clinically stable toxicities requiring ongoing medical management, such as hypothyroidism from prior immune checkpoint inhibitor treatment).
- 3\. Subjects may not be receiving any other investigational agents for the treatment of the cancer under study.
Other illness
- 5\. History of allergic or hypersensitivity reactions attributed to compounds of similar chemical or biologic composition to Acetadote.
- 6\. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that, in the opinion of the investigator, would limit compliance with study requirements.
Other
- 4\. Brain metastases
- 7\. Subjects must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants.
Who the study is looking for
- 1\. Glioblastoma
- 2\. Newly diagnosed with no prior surgery, radiation, chemotherapy, or other tumor-treating agent
- 3\. Age ≥18 years
- 4\. KPS \> 70
- 5\. Adequate organ and marrow function as defined below:
- \- Bilirubin ≤1.5 times upper limit of normal
- \- AST and ALT ≤ 3 times ULN
- \- Creatinine ≤ 1.5 x ULN and/or GFR ≤ 60 mL/min
- -ANC ≥ 1000 cells/ul
- \- Platelet ≥ 100,000/ul
- \- Hemoglobin ≥ 9 g/dl
- 6\. All men, as well as women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 7 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
- 6a. A female of child-bearing potential is any woman (regardless of sexual orientation, marital status, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
- \- Has not undergone a hysterectomy or bilateral oophorectomy; or
- \- Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).
- 7\. Ability to understand and the willingness to sign a written informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Texas Southwestern Medical Center Coordinator of this site? Confirm its status | Dallas | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.